NCT06422403View on ClinicalTrials.gov

A Value-Driven Study on Reducing Immune Checkpoint Inhibitor Dosing Frequency in Advanced Cancers

PHASE2RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

November 25, 2024

Primary Completion Date

March 30, 2029

Study Completion Date

December 31, 2029

Conditions
Carcinoma, HepatocellularGastric AdenocarcinomaGastroEsophageal CancerOesophageal CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma
Interventions
DRUG

Extended Dosing Interval - A

Nivolumab 360mg 6 weekly (up to 2 years) + XELOX Nivolumab 240mg 4 weekly (up to 2 years) + FOLFOX

DRUG

Extended Dosing Interval - B

Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)

DRUG

Extended Dosing Interval - C

Pembrolizumab 200mg 6 weekly (up to 2 years)

DRUG

Standard of Care - A

Nivolumab 360mg 3 weekly (up to 2 years) + XELOX Nivolumab 240mg 2 weekly (up to 2 years) + FOLFOX

DRUG

Standard of Care - B

Bevacizumab + Atezolizumab 1200mg 3 weekly (up to 2 years)

DRUG

Standard of Care - C

Pembrolizumab 200mg 3 weekly (up to 2 years)

Trial Locations (1)

Unknown

RECRUITING

Department of Hematology-Oncology, National University Hospita, Singapore

All Listed Sponsors
lead

National University Hospital, Singapore

OTHER